Luke Gilbert joins the Scientific Advisory Board (SAB) of Myllia Biotechnology
Myllia Biotechnology, a leading innovator in the field of single-cell CRISPR screening technologies, is pleased to announce the addition of Dr. Luke Gilbert to its esteemed Scientific Advisory Board (SAB). Dr. Gilbert brings a wealth of expertise in synthetic biology, functional genomics, and cancer biology to the Myllia team.
Dr. Gilbert completed a distinguished postdoctoral stay at the laboratory of Jonathan Weissman, where he performed ground-breaking work on CRISPR interference and activation. He now holds a dual affiliation with the University of California, San Francisco (UCSF) and the esteemed Arc Institute, further solidifying his position as a prominent figure in the field.
At UCSF and Arc Institute, Dr. Gilbert's laboratory is at the forefront of scientific innovation, focusing on the development of new genetic tools to systematically unravel the functions of the genes encoded by the human genome. Their primary mission is to address critical challenges in deadly human cancers, particularly metastasis and drug resistance.
Myllia Biotechnology, known for its pioneering CROP-Seq (CRISPR Droplet Sequencing) workflow, has established a paradigm for next-generation CRISPR screens, enabling the mapping of thousands of genetic perturbations on the global transcriptome at single-cell resolution. This powerful approach holds significant promise in identifying novel drug targets, elucidating unknown mechanisms of drug actions, and comprehending genetic variants associated with disease risk.
Dr. Gilbert's addition to the Scientific Advisory Board is anticipated to be a transformative milestone for Myllia. His profound expertise in single-cell CRISPR screens will undoubtedly contribute to the company's ongoing success. Additionally, Dr. Gilbert is poised to play a pivotal role in promoting Myllia's presence in the United States, further solidifying the company's position as a global leader in CRISPR screening technologies.
Luke Gilbert commented: "I have been impressed with Myllia’s technology platform since the inception and am looking forward to working with the team on advancing the frontiers of single-cell CRISPR screening."
Tilmann Buerckstuemmer, Chief Scientific Officer (CSO) of Myllia Biotechnology, warmly welcomes Dr. Gilbert to the Scientific Advisory Board. "We are thrilled to have someone of Luke's caliber join Myllia's SAB," says Buerckstuemmer. "His exceptional knowledge and track record in single-cell CRISPR screening make him a valuable addition to our team."
Dr. Gilbert's appointment is a testament to Myllia Biotechnology's commitment to advancing the field of CRISPR screening and underscores the company's dedication to bringing cutting-edge technologies to the forefront of scientific research.
For more information: www.myllia.com
Henrik Schmidt on behalf of Myllia Biotechnology
+43 1 9346880 200